U&ctives. This study sought to compare the relation hehveen smoking and the -M-day and 6-month outcome after acute myncardial inlarction in an Israeli nationwide survey.
Buckgmund. Studies before and during the thmmbolytic era reported similar or lower early mortality after acute myomrdial infarction in smokers than in nonsmokers. This Rnding is intriguing and may be misleadinlt because numemuj epidemiolotjc studies have clearly shown that smoking is an independent risk factnr for athemsclemsis, myocardial infarctinn and death.
M&I&. The study cohort comprised 999 consecutive patients with an acute myocardiol infarction from a prospective nationwide survey conducted during January and February I!84 in all comnarv care units opemting in Israel. The pmgnosis of 367 patients (37%) who wet-smokers tcurrent smokers and those who smoked up to I month before admission) was compared with that nf 632 nnnsmnkers (past smokers or those who never smoked).
Resullu. Smokers were un average 1U years younger and were more frequently men and patients with a family history ,of coronary heart disease and inferior infarction and less frequently patients with a previous infarction or a history of angina, hypertension and diabetes than nonsmokers. Smokers also had a lower Dcspitc the fact th:t literally all epidemiologic studies have shown th;,t smoking is an independent risk factor for atherosclerosis. acute myocardial infarction and death (l-3), some investigators (4-h) have reported a lower in-hospital mortality rate after myocardial infarction in smokers than nonsmokers. Surprisingly. smoking emerged as an independent predictor of hcttcr prognosis after acute myocardial infarction in the prcthromholytic (45) and thromholytic eras (h-7). A prssihlc incidence of congestive heart failure on adu~ission or duriw the hospital period. Thmmhoiytic therapy (49% vs. 40%, p < 0.01) and aspirin (89% vs. W%, p c 0.001) were admiuistcred more frequently in smokers than wnstuokers. The crude M-day (6.W vs. 15.7%) and cumulative &munth (7.9% vs. 215%) mortality rates were signitisantly lower tp < 0.0001 for both) in smokers than nonsmokers, respectively. However, after adjustment fur age. baseline characterlslies, thmmbolytic therapy and invasive mmnary prrxedures, the lower 30- without thrombolysis and thereby to assess the mechanisms underlying the better prognosis among smokers.
Methods
Palknls.
A nationwide prospective survey was performed during a 2-month period (January and February 1994) in all 25 coronary care units operating in Israel. Demographic, histnrical and clinical data were collected on special forms for all 1,012 participants. Thirteen patients with incomplete data were excluded from the analysis. The diagnosis of acute myocardial infarction was based on the presence of two of the following: pain suggestive of myocardiel infarction lasting for at least 30 min; unequivocal new electrocardiographic (ECG) alterations (Q/OS or ST-T segment or both, and T wave changes); or increase of at least two of the three serum cardiac enzymes (creatine kinase, aspartate aminotransferase and lactate dehydrogenase) to more than 1.5 times the upper normal limit, or concomitant increase in creatine kinase (CK) and MB isoenxyme. Cunrnf sm&rs were defined as patients who were smoking or had quit smoking within 1 month before admission. Nonsmokers were defined as patients who had either never smoked or had stopped smoking > 1 month before admission. Thirtyday and 6-month mortality was assessed from the medical charts and by matching the identification number of patients with the Israeli National Population Registry.
Statistical raalysis. All analyses were performed using SAS statistical software (12). Chi-square and I tests were used to determine the significance of the differences between proportions and mean values, respectively, where appropriate. Results of continuous variables are -eported as mean value -t SD. so-sided p values are reported.
A direct age adjustment (95% confidence interval [Cl] ) was performed to compare mortality rates between smokers and nonsmokers. To compare 30day mortality in smokers and nonsmokers in terms of odds ratio ([OR] with 95% Cl; where nonsmokers were the reference group, OR ,= 1). a stepwise logistic regression analysis (SAS Logistic Procedure) was performed, adjusting for age, gender, diabetes, hypertension, family history of coronary artery disease, history of angina. previous infarction, anterior Q wave during the index infarction, systolic blood pressure ~100 mm Hg, heart rate >100 oeats/min and Killip class ~11 on admission, thmmbolytic .387 (bl) lIlz11
204 (33) 183 (29) 311(W) X3 (34) 144 (3) 52 (U) 24 (4) 14 (4) 109 ( therapy and invasive coronary procedures (coronary angiography, coronary angioplasty and coronary artery bypass grafting) during the hospital period. A stepwise Cox proportional haaards regression model (SAS PHREG Procedure) adjusting for the same variables and for in-hospital complications. such as congestive heart failure and paroxysmal atrial fibrillation. was used to compare cumulative 6-month mortality in smokers versus nonsmokers in terms of hazard ratio ([HR] and 95% CI; where nonsmokers were the reference gmup, HR = 1). A variable was allowed to enter into the model if it made a significant contribution at the 0.10 level of significance and was removed if after subsequent addition of other variables to the model, it no longer made a contribution at the 0.15 level of significance. The sample size was large enough to produce a power of 0.8, if the OR for smokers to nonsmokers is 0.50, under a type 1 error of alpha = 0.1. Unadjusted survival curves were constructed using the method of Kaplan-Meier. The significance of the difference between the survival curves was assessed by the log-rank test (SAS Lifetest Pnxedure). Adjusted survival curves were produced using variables entered into the best selected Cox model (SAS PHREG Procedure).
Results 6aseiine rhulctcristks. ,The baseline characteristics of 999 patients 'tith acute mjroeardial infarction-participating in the survey, including 367 (37%) smokers and 632 nonsmokers, 'are presented in Table 1 . Smokers were on average 10 years younger (57 2 12 vs. 67 f: 11 years, p < O.tMOl): and were more frequently menc patients with a family history of coronary artery disease and Xerior infarction and less frequently pa- In-hospital complications and management. On admission. smokers had a better Killip class and lower heart rate than nonsmokers (Tat&! 2). Congestive heart failure. shock, severe mitral regureiration! paroxysmal atrial fibrillation and new bundle branch block were significantly less frequent among smokers than nonsmokers. although peak CKestimated inf;:r;t size was similar in both groups (Table 2) . i"onsmokcrs were more frequently treated with digitalis, ;mgiotenc;n-converting enzyme inhibitors and diuretic drugs and Ir:,s frequently with calcium ant. gonists. thrombolytic thcripg. hcparin and aspirin than were smokers (Table 3) . C,lronav angiography and coronary artcry bypass graft surgery were performed in similar proportions in both groups, whereas smokers more often underwent coronary angioplasty (Table 3) .
Mortality. The crude 3Wday mortality rate was significantly lower in smokers than nonsmokers (6.0% vs lS.7??. respcctivcly, p L< NOOI). However, after direct age adjustment. the W-day morlalily rates were not significantly ditfercnt belween smokers (8.W, 9.5';; <'I 5.0% to 12.5%) and nonsmokers (13.SG, 955 Cl II.O% to 16.0%,) ( Comparison ktween smokers with and without thromholysis. Among active smokers (n = 367). 181 patients (49%) were treated with thrombolysis. The baseline characteristics and in-hospital complications (Table 5 ) of smokers with (n = 181) and without thrombolysis (n = 186) were comparable. Smokers with thrombolysis more often had a Q wave infarction and complex ventricular arrhythmias (ventricular tachycardia or fibrillation).
whereas a previous infarction and paroxysmal atrial fibrillation were more frequent among smokers inehgible for thrombolysis. Peak CK levels were higher among smokers with thrombolysis.
Medical treatment and rate of invasive coronary procedures performed during the index hospital period were similar in both groups except for heparin. which was given more frequently to smokers with thrombolysis (Table 6) .
Thirty-day mortality rates were similar in smokers with and without thrombolysis (6.19 and 5.9%. respectively). The cu- mulative 6-month crude mortality rate among both groups of patients was 7.3% and 8.6%. respectively (p = 0.53 hy log-rank test) (Fig. 2) .
Discussion
The main tinding of the present study is that the seemingly better prognosis of smokers after acute myocardial infarcrion may ha attributed to their more favorable risk profile and that after adjusting for age and other confounding variahlcs, smoking was no longer an independent predictor of better prognosis.
Revious studies. Our findings from a nationwide survey are in accordance with some recent clinical trials (10X3--13. In the Gruppo Italian0 per lo Studio Della Soprawivenza trell'lnfarto Miocardico (GISSL2) study (14) including 9.720 patients, smokers had a better in-hospital and 6-month postdischarge prognosis, which disappeared after multivariate adjustment for clinical variables (age, gender, number of hours between symptoms onset to hospital admission, Killip class. infarct location, diabetes, hypertension, previous angina, hjdy mass index, peak CK levels and number of ECG lcads with ST segment elevation). Data from the Myocardial Infarction Triage and Intervention (MITi) Project (15). in which twothirds of the patients did not receive thrombolysis. also did not identify smoking as an independent predictor of low mortality after adjustment (age. reinfarction, congestive heart failure, cardiogenic shock and recurrent chest pain).
In contrast t0 these findings, a number of studies conducted in the prethrombolytic and thrombolytic eras foilnd that the higher in-hospital mortality among nonsmokeix remained significant even after adjustment for baselint characteristics (4) (5) (6) (7) 16, 17 (29) 54 (29) 31(17) 37 (20) 43 (24) 56 (30) 36 (20) 43 (23) 91.5) I i< 1) 144 (80) I05 (57) II (6) IO (5) (7) 18(laJ 11 (b) 33 (18) 11 (6) 17 (9) 21 (11, 6 (3 5 (3) 8 (4) 3 (2) 17 (9 I9 (10) I (< 1) I(< 1) Tables I and 2. remained so after adjustment for baseline differences, ECG findings, laboratory data and drugs at entrv (relative risk 0.55, 9% CI 0.33 to 0.93). Sirr.iii;r findings were noted by Kelly et al. (4) in 2,955 patients (excluding ex-smokers) with an acute myocardial infarction, where adjusting for age and other variables (blood urea, history of heart failure, angina, myocardial infarction and pulmonary congestion on admission) reddced but did not cancel the survival differential favoring smokers at 1 month, but did eliminate the mortality differences at 6 and 12 months. In two recent large thrombolytic trials (6,7), the mortality rate of smokers was lower than that of ex-smokers or nonsmokers even after adjustment for baseline characteristics. In the study by Barbash et al (61, including 2,366 nons;nokers, 2,244 ex-smokers and 3,649 active smokers from the International Tissue Plasminogen Activator/ Streptokinase Mortality Trial, a 1 A-fold increase in in-hospital and &month mortality rates was demonstrated for nonsmokers after adjusting for baseline characteristics similar to those in our study. Similar findings for 30-day mortality, were reported from the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-I) study (7) in 41,021 patients treated with thrombolysis but not in the angiographic substudy (lg). In this subgroup, adjustment for clinical and angiographic variables, including coronary anatomy, TIM1 grade 3 flow and left ventricular function, yielded similar mortality in smokers and nonsmokers (OR 0.93 for smokers). Similar findings were observed by Grines et al. (9) in patients from the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) trials. Smokers had a better 42day survival after adjustment for baseline clinical variables (age, systolic blood pressure, and infarct location) but not after adjustment for acute Bngiographic variables, including nvmber of diseased ve&els, left ventricular ejection fraction and TIMI flow "grade. Thus, a partial explanation for the discrepant findings in the different studies may be related to the different variables controlled for, in particular the angiographic data. Furthermore, because TIMI grade 3 flow is more prevalent among smokers after thrombolysis (9-11) and may explain in part their improved survival. it may be inappropriate to ctilltrol for this variable in the multivariate analysis. The most likely explanation for the discrepancy between our study and previous studies (6?7.3,18) is that those studies did not include consecutive patients as was done in our sumey. Rather. they included only patients eligible for a thrombolytic trial, who are generally younger and have better baseline characteristics and prognosis than those ineligible for thrombolytic therapy. a limitation recognized by Barbash et al. (18) for the GUSTO-I study and by others (8) . Although our study is much smaller than the two aforementioned ones (6.7.18). It is based on a consecutive series of unselected patients admitted to all coronary care units in Israel during a Z-month period, including periphera!, secondary and tertiary hospitals: therefore, its rcstiiis may be more generally applicable to patients with acute myoctirdial infarction in the community.
Possible mechanisms for better outcome in smokers. Several factors may explain the paradox of a seemingly better early prognosis of smokers after acute myocardial infarctio?. In our study, as in most others, age was a strong independent predictor of mortality after myocardial infarction. In the Secondary Prevention Reinfarction Israeli Nifedipine Trial (SPRINT) Registry (19), a IO-year increment of age was associated with a twofold increase in in-hospital mortality. In the GUSTO-I trial (7), age was the most significant factor influencing 30-day mortality and provided nearly half the prognostic information in the multivariate logistic model. In all previous studies, smokers experienced myocardial infarction at a younger age than nonsmokers (4-6.10,11.13.18,20). In the present study, smokers were 10 years younger than nonsmokerr. It was also rhown (20) that the adjsstcd age for a first nonfatal infarction progressively declined with increasing smoking exposure. Thus, the younger age of smokers favors a better prognosis during the early phase of acute myocardial infarction.
Smokers also have a more favorable risk profile other than age (4-6.9.11.13,18,20) . In the present study, the frequency of previous infarction, diabetes and hypertension (7.13,21.22) was lower among smokers than nonsmokers.
Smoking is arrhythmogenic (23) . increases the incidence of late potentials on the signal-averaged ECG and may increase the risk of ventricular tachycardia and sudden death (24) . Therefore, smokers may be more prone to prehospital sudden death than r.cnsmokers (25.26) . thus artificially reducing the in-hospital mortality after acute myocardial infarction.
The hospit;ll course of nonsmokers was more complicated than that of smokers, ,probably due to their older age and worse baseline characteristics. In our study. congestive heart failure and cardiogenic shock were 3-times more common in nonsmokers than in smokers. Nonsmokers more frequently received digitalis aitd diuretics. Similar findings were noted in previous studies (6,13.18) .
A smaller infarction may lead to better survival in smokers. Infarct size was smaller in smokers at %I min after initiation of thrombolytic therapy (9,18) but not at hospital dixharge (9.10.X). In our study. peak CK levels were similar in smokers and ncinsmokers. Similar findings were noted in some s!udies (10.20) but not in others ($11). Smokers had a higher frequcncy of inferior infarction than nonsmokers (5,6.10.11,13.18). usuallv associated wi;h a smaller infarction. Nonetheless. even if the infarct size is similar in smokers and nonsmokers. nonsmokers might have developed more often heart faliure on admission and during the hospital course as a result of diastolic dysfun&n associated with advanced age. hypertension and dia!,rtes.
In our study, altii;ktrJ were treated more frequently with thrombolysis and invasive coronary interventions. probably because they were younger and had less contraindications for these modes of therapy. Thus, smokers may have benefited more from these innovative therapies than nonsmokers.
Smokers have higher fibrinogen. hematocrit and Factor VII levels (9,11.27,28) . impaired endothelial function (29) and vasospasm (30) . predisposing them to thrombus formation and myocardial infarction (31) . Thus. coronary obstruction in smokers might be more thromhogenic and less atherosclerotic in nature. A large thrombotic component in smokers may be more amenable to vasodilation and thrombolysis and hence to more complete reperfusion. leading to improved early infarctrelated coronary artery flow and less residual atheromatous stenosis after thrombolysis. Smokmg precipitates myocardial infarction at an earlier age with a lesser degree of coronary artcry disease (13,18.32). In the Coronary Artery Surgery Study (CASS) registry (33). a negative correlation was noted between the extent of cr:onary disease and smoking. McKcnna et 31. (31) A.! \ L .; *ii:!! riormal coronary arteries were more frcqklrnlii I. bihlo: iir-l .-!n: smokers than nonsmokers after acute myocardial infar.W:lir:: ..kgesting a higher rate of vasospastic or thrombotic occlusion. Recenti,, several studies pointed out that the patency rate (TIM1 grade 3 flow) (9-l 1,18) and lumen diameter measured early after thrombolytic therapy are greater in smokers than nonsmokers (9) . supporting the thrombogenic mechanism of infarction among smokers. Consequently. smokers may have a smaller infarction and may be left with less Severe urlderlying narrowing than nonsmokers (9) . which may explain, at least in part, their better curvival.
Uniqueness or the study. This survey of consecutive. unselected. patients with acute myocardial infarction confirms observations made earlier in randomized clinical trials. and its findings may be morz generally applicable than those obtained from selected patients entered in clinical trials. In addition. previous studies co!nparcd the prognosis of smokers with that o! ncinsmokers after acute myocardial infarction, either in the prethromolytic or current thromoolyric era. The present survey allowed us to compare the outcome between smokers with and without thrombolysis: two groups with similar low risk proliles who were otherwise mayaged similarly (Tables 5 and 6 ). Remarkably, mortalit); was similar and low in both groups of smokers, suzesting that the favorable outcome of smokers after myocardial infarction is probably related lo their better baseline characteristics and their younger age. The lack of observed mortality difference between smokers treated versus not treated with a thiombolytic agent may also be related to, the small numbei of patients in the, present ,sttidy and io the !ow mortality rate of young patients with m)ocardial infarction. (j5). Our finding is in contrast to that observed in the APSAC Intervention Mortality Study, (AIMS) trial (36) . where the mortality was significantly lowei among smokers trealed with thrombolysis than in those not treated with thrombolysis. The reason for this discrepancy with our study seems to be due to differences in the patient grotips of the two studies. Whereas AIMS was a randomized trial in which all patients ~70 years old treated within 6 h of symptoms were eligible for thrombolysis, our nationwide survey included all patients admitted with an acute myocardial infarction. Patients not given thrombolysis were those who were not eligible for it. It is also conceivable that major differences in the use of aspirin, which was much lower in the AIMS study than in our study (2% vs. 85%. respectively), influenced differently the response to thrombolysis and the outcome m smokers.
Limitations of the study. We could not differentiate between past-smokers and those who had never smoked. The prognosis of ex-smokers after acute myocardial infarction is intermediate between that of current smokers and nonsmokers (6, 7, 10, 13, 14) . Thus, the mortality rate in our nonsmoking patients may be diluted with ex-smokers and, thus, underestimated. We cannot exclude the possibility that patients with a more adverse risk profile, and thus a worse prognosis, quit smoking before the index infarction because of worsening of their cardiac condition.
We do not have information regarding cessation of smoking after the acute event, and therefore we could not evaluate its impact on outcome after the acute infarction. However, in general? posthospital period cessation rates exceed 50% (37) .
The present study includes data on in-hospital complications and 6-month mortality but no information on nonfatal cardiac even!s during the follow-up period. Even though the difference in mortality rates between smokers and nonsmokers was noI significant, we cannot exclude the possibility that the postdischarge morbidity of smokers may differ from that of nonsmokers, especially among those who continued smoking (38,39).
Sum~aq. 'ine present study in unselected, consecutive patients with acute myocardial infarction suggests that smokers have an early survival advantage over nonsmokers. However, the seemingly better early prognosis could be attributed to the younger age, lower risk profile and less eventful hospital course of smokers. Smokers present with acute myocardial infarction about a decade earlier than past or nonsmokers. Efforts to discourage smoking should continue. Larger community-based studiec in patients with acute myocardial infarction from different countries, assessing &ssical and new risk factors [lipoprotein(a), polymorphism in the angiotensin-converting enzyme gene] and angiographic and hemostatic data may shed further light on the mechanism of the seemingly better prognosis of smokers.
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